All lobbying filings

DLA PIPER LLP (US)

Lobbying for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Trade association of innovative biopharmaceutical research companies.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · District of Columbia · House · Senate · $60,000.00 income · posted Apr 21, 2025

Official filing document

Bills named in this filing 3

S 832
EPIC Act of 2025
SCONRES 7
An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal ye…
HCONRES 14
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…

Lobbying activity 6

Pharmacy

Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.

Health Issues

S. 832, EPIC Act of 2025.

Medicare/Medicaid

Medicare policies.

Budget/Appropriations

S. Con. Res. 7, Budget Resolution for FY2025, provisions impacting pharmaceuticals. H. Con. Res. 14, Budget Resolution for FY2025, provisions impacting pharmaceuticals.

Defense

National security issues related to pharmaceutical industry, including supply chain.

Trade (domestic/foreign)

Trade policies and agreements, including IP protections, and administrative tariff actions.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.